Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

SD-998, thrombin inhibitor

April 19, 1996

New series of thrombin inhibitors claimed by Thomae

April 19, 1996

Novel prostaglandin D2 agonists from Glaxo Wellcome

April 12, 1996

XR-300 fibrinogen antagonist in preclinical testing

April 12, 1996

Merck & Co. describes fibrinogen antagonists

April 12, 1996

Fibrinogen antagonists from Yamanouchi

April 12, 1996

ATIII in development at Genzyme Transgenics

April 12, 1996

Neutralase to enter phase II

April 12, 1996

SB-214857 in preclinical studies

April 5, 1996

Scripps Research Institute reports fibrinogen antagonists

April 5, 1996

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...